News

1

children sitting under a mosquito bed net.

Single-dose Kozenis (tafenoquine) approved for children with Plasmodium vivax malaria by Australian Therapeutic Goods Administration

quote and photo of person quoted

P. vivax radical cure in Latin America: regional coordination to advance malaria elimination

microbiology laboratory in Porto Velho, Brazil

First real-world use of new protocol for P. vivax case management in Brazil – a Health Ministry and MMV collaboration

quote and photo of people quoted

New Partnership launched to accelerate elimination of relapsing P. vivax malaria that poses a risk to an estimated 2.5 billion people worldwide

Gloved hands performing STANDARD G6PD test

STANDARD G6PD Test receives regulatory approval by the Australian Therapeutic Goods Administration

APMEN VxWG Chair and co-Chair looking at screen

New Chair and co-Chair of the APMEN Vivax Working Group announced

health centre in Peru

New single-dose medicine to prevent relapse of P. vivax malaria just approved in Peru

Mother holding young child in Thailand

GSK, MMV filing for Kozenis (tafenoquine) in paediatric populations with Plasmodium vivax malaria accepted by Australian Therapeutic Goods Administration

palm of hand face up holding dispersible tablets of tafenoquine

Study finds malaria drug can also prevent relapse in children

crowd of children looking directly at the camera

GSK and MMV present positive data on treatment for Plasmodium vivax malaria in children from 6 months up to 15 years of age

Webinar participants on screen

Event Highlights from the VivAccess Hosted Symposium at Virtual ASTMH: Accelerating New Tools for Radical Cure of Vivax Malaria from Clinical and Operational Research to Policy

Woman conducting training session - showing materials to participants

G6PD Operational Research in Vietnam

Pages

1

Events